Development and preclinical evaluation of a new F(ab′)2 antitoxin against botulinum neurotoxin serotype A

Biochimie

Volumn 92, Issue 10, 2010, Pages 1315-1320

  Yu, Yun Zhou ^a   Zhang, Shu Ming ^b   Wang, Wen Bing ^a   Du, Yun ^a   Zhu, Heng Qi ^a   Wang, Rui Lin ^a   Zhou, Xiao Wei ^a   Lin, Jian Bo ^a   Wang, Shuang ^a   Yu, Wei Yuan ^a   Huang, Pei Tang ^a   Sun, Zhi Wei ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^b NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

Author keywords

Antitoxin; Botulism; Immunotherapy; Preclinical evaluation

Indexed keywords

BOTULINUM ANTISERUM; BOTULINUM TOXIN A; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BOTULISM; CONTROLLED STUDY; DISEASE COURSE; DOG; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; HORSE; IMMUNIZATION; IMMUNOGENICITY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PARALYSIS; TREATMENT OUTCOME;

ANIMALS; ANTITOXINS; BOTULINUM TOXINS; BOTULISM; DOGS; DRUG EVALUATION, PRECLINICAL; IMMUNIZATION; IMMUNOGLOBULIN FAB FRAGMENTS; MICE; NEUROTOXINS; TREATMENT OUTCOME;

CANIS FAMILIARIS; EQUIDAE; MUS;

EID: 77957107062     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2010.06.010     Document Type: Article

References (27)

1. Turton K., Chaddock J.A., Acharya K.R. botulinum and tetanus neurotoxtins: structure, function and therapeutic utility. Trends Biochem. Sci. 2002, 27:552-558.
2. Schiavo G., Matteoli M., Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 2000, 80:717-766.
3. Dembek Z.F., Smith L.A., Rusnak J.M. Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities. Disaster Med. Public Health Prep. 2007, 1:122-134.
4. Arnon S.S., Schechter R., Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., Fine A.D., Hauer J., Layton M., Lillibridge S., Osterholm M.T., O'Toole T., Parker G., Perl T.M., Russell P.K., Swerdlow D.L., Tonat K. Working group on civilian biodefense, botulinum toxin as a biological weapon. J Am Med Assoc 2001, 285:1059-1070.
5. Mayer C.N., Holley J.L.T., Brooks Antitoxin therapy for botulinum intoxication. Rew. Med. Microbiol. 2001, 12:29-37.
6. Jones R.G., Alsop T.A., Hull R., Tierney R., Rigsby P., Holley J., Sesardic D. Botulinum type A toxin neutralisation by specific IgG and its fragments: a comparison of mouse systemic toxicity and local flaccid paralysis assays. Toxicon 2006, 48:246-254.
7. Byrne M.P., Smith L.A. Development of vaccines for prevention of botulism. Biochimie 2000, 82:955-966.
8. Middlebrook J.L. Production of vaccines against leading biowarfare toxins can utilize DNA scientific technology. Adv. Drug Deliv. Rev. 2005, 57:1415-1423.
9. Clayton M.A., Clayton J.M., Brown D.R., Middlebrook J.L. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect. Immun. 1995, 63:2728-2742.
10. Tavallaie M., Chenal A., Gillet D., Pereira Y., Manich M., Gibert M., Raffestin S., Popoff M.R., Marvaud J.C. Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies. FEBS Lett. 2004, 572:299-306.
11. Baldwin M.R., Tepp W.H., Pier C.L., Bradshaw M., Ho M., Wilson B.A., Fritz R.B., Johnson E.A., Barbieri J.T. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect. Immun. 2005, 73:6998-7005.
12. Ravichandran E., Al-Saleem F.H., Ancharski D.M., Elias M.D., Singh A.K., Shamim M., Gong Y., Simpson L.L. Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect. Immun. 2007, 75:3043-3054.
13. Yu Y.Z., Li N., Zhu H.Q., Wang R.L., Du Y., Wang S., Yu W.Y., Sun Z.W. The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate. Vaccine 2009, 27:2816-2822.
14. Yu Y.Z., Sun Z.W., Li N., Wang S., Wang R.L., Yu W.Y. Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine. Clin. Vaccine Immunol. 2008, 15:1819-1823.
15. Byrne M.P., Smith T.J., Montgomery V.A., Smith L.A. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect. Immun. 1998, 66:4817-4822.
16. Smith L.A. Development of recombinant vaccines for botulinum toxin. Toxicon 1998, 36:1539-1548.
17. Gurkan C., Ellar D.J. Recombinant production of bacterial toxins and their derivatives in the methylotrophic yeast Pichia pastoris. Microb. Cell Fact. 2005, 4:33. 10.1186/11475-2859-4-33.
18. Stahl C., Unger L., Mazuet C., Popoff M., Straub R., Frey J. Immune response of horses to vaccination with the recombinant Hc domain of botulinum neurotoxin types C and D. Vaccine 2009, 27:5661-5666.
19. Smith L.A., Rusnak J.M. Botulinum neurotoxin vaccines: past, present, and future. Crit. Rev. Immunol. 2007, 27:303-318.
20. Chinese Pharmacopoeia Commission Pharmacopoeia of the people's Republic of China (Volume III), Appendix XII H: The Potency Assay of Botulinum Antitoxin 2005, Appendix, People's Medical Publishing House, Beijing, 69-70.
21. Tacket C.O., Shandera W.X., Mann J.M., Hargrett N.T., Blake P.A. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am. J. Med. 1984, 76:794-798.
22. Middlebrook J.L., Brown J.E. Immunodiagnosis and immunotherapy of tetanus and botulinum neurotoxins. Curr. Top. Microbiol. Immunol. 1995, 95:89-122.
23. Franz D.R., Jahrling P.B., Friedlander A.M., McClain D.J., Hoover D.L., Bryne W.R., Pavlin J.A., Christopher G.W., Eitzen E.M. Clinical recognition and management of patients exposed to biological warfare agents. J Am Med Assoc 1997, 278:399-411.
24. Gelzleichter T.R., Myers M.A., Menton R.G., Niemuth N.A., Matthews M.C., Langford M.J. Protection against botulinum toxins provided by passive immunization with botulinum human immune globulin: evaluation using an inhalation model. J. Appl. Toxicol. 1999, 19:S35-S38.
25. McLellan K., Gaines Das R.E., Ekong T.A., Sesardic D. Therapeutic botulinum type A toxin: factors affecting potency. Toxicon 1996, 34:975-985.
26. Black R.E., Gunn R.A. Hypersensitivity reactions associated with botulinal antitoxin. Am. J. Med. 1980, 69:567-570.
27. Mayers C.N., Veall S., Bedford R.J., Holley J.L. Anti-immunoglobulin responses to IgG, F(ab′)2, and Fab botulinum antitoxins in mice. Immunopharmacol. Immunotoxicol. 2003, 25:397-408.